Michael Gelband’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Michael Gelband’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,466	Closed	-$359K	–	2516
2022 Q2	$359K	Buy	+2,466	New	+$315K	﹤0.01%	1468
2021 Q2	–	Sell	-5,305	Closed	-$363K	–	3092
2021 Q1	$363K	Buy	+5,305	New	+$429K	0.01%	1548
2020 Q4	–	Sell	-30,564	Closed	-$1.99M	–	2597
2020 Q3	$1.99M	Buy	+30,564	New	+$2M	0.04%	408
2019 Q3	–	Sell	-21,894	Closed	-$959K	–	1807
2019 Q2	$959K	Buy	+21,894	New	+$1.23M	0.04%	259

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SFM

Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Michael Gelband's BHVN Position: Q3 2022 in Review

Michael Gelband sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 2,466 shares — an estimated $359K sold.

Michael Gelband first reported a position in BHVN in Q2 2019 and held it in 4 quarters. The position peaked at $1.99M in Q3 2020. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Michael Gelband reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Michael Gelband sold 2,466 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $359K.
Michael Gelband first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 4 quarters.
Michael Gelband's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.99M in Q3 2020.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.